Sinus floor elevation using implants coated with recombinant human bone morphogenetic protein-2: micro-computed tomographic and histomorphometric analyses

Daniel S. Thoma, So Ra Yoon, Jae Kook Cha, Hyun Chang Lim, Jung Seok Lee, Seong Ho Choi, Ui Won Jung

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: The objective of this study was to determine the validity of a graft-free sinus floor elevation (SFE) procedure with simultaneous placement of recombinant morphogenetic protein-2 (rhBMP-2)-coated implants compared to uncoated control implants. Methods: In 10 rabbits, SFE was performed on both sides. Dental implants were randomly placed in the sinus filled with a blood clot. Test implants were coated with rhBMP-2, whereas in the control group, implants were uncoated. Micro-computed tomographic and histomophometric analyses were performed at 4 and 8 weeks, including measurement for newly formed bone height (NBHm). Results: Bone formation was evident along the implant surfaces up to the apex in test, but limited in control implants at 4 weeks. NBHm amounted to 5.1 mm (Q1 = 4.1; Q3 = 5.3) for test implants and to 3.4 mm (2.6; 3.7) for control implants at 4 weeks. NBHm then decreased to 8 weeks (3.4 mm (3.3; 3.7)) for test implants, whereas in control sites, NBHm increased slightly to 4.4 mm (4.1; 4.5) (p = 0.1250; p = 0.6250). Conclusions: Implants coated with rhBMP-2 presented a strong osteogenic reaction at 4 weeks with more favorable outcomes in terms of bone formation along the implant surface up to the apex compared to uncoated control implants. Remodeling and resorption process between 4 and 8 weeks did not further improve the outcomes in the test, but in the control group. Clinical relevance: The use of rhBMP-2-coated implants in a graft-free SFE might show an advantage in early implant stability to prevent collapse of membrane. However, a potential clinical benefit still needs to be proven.

Original languageEnglish
Pages (from-to)829-837
Number of pages9
JournalClinical Oral Investigations
Volume22
Issue number2
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Osteogenesis
Transplants
Control Groups
Dental Implants
Thrombosis
Rabbits
Bone and Bones
Membranes
recombinant human bone morphogenetic protein-2

All Science Journal Classification (ASJC) codes

  • Dentistry(all)

Cite this

@article{f1c60f141b6542c589bfdae2e9ce8b97,
title = "Sinus floor elevation using implants coated with recombinant human bone morphogenetic protein-2: micro-computed tomographic and histomorphometric analyses",
abstract = "Objectives: The objective of this study was to determine the validity of a graft-free sinus floor elevation (SFE) procedure with simultaneous placement of recombinant morphogenetic protein-2 (rhBMP-2)-coated implants compared to uncoated control implants. Methods: In 10 rabbits, SFE was performed on both sides. Dental implants were randomly placed in the sinus filled with a blood clot. Test implants were coated with rhBMP-2, whereas in the control group, implants were uncoated. Micro-computed tomographic and histomophometric analyses were performed at 4 and 8 weeks, including measurement for newly formed bone height (NBHm). Results: Bone formation was evident along the implant surfaces up to the apex in test, but limited in control implants at 4 weeks. NBHm amounted to 5.1 mm (Q1 = 4.1; Q3 = 5.3) for test implants and to 3.4 mm (2.6; 3.7) for control implants at 4 weeks. NBHm then decreased to 8 weeks (3.4 mm (3.3; 3.7)) for test implants, whereas in control sites, NBHm increased slightly to 4.4 mm (4.1; 4.5) (p = 0.1250; p = 0.6250). Conclusions: Implants coated with rhBMP-2 presented a strong osteogenic reaction at 4 weeks with more favorable outcomes in terms of bone formation along the implant surface up to the apex compared to uncoated control implants. Remodeling and resorption process between 4 and 8 weeks did not further improve the outcomes in the test, but in the control group. Clinical relevance: The use of rhBMP-2-coated implants in a graft-free SFE might show an advantage in early implant stability to prevent collapse of membrane. However, a potential clinical benefit still needs to be proven.",
author = "Thoma, {Daniel S.} and Yoon, {So Ra} and Cha, {Jae Kook} and Lim, {Hyun Chang} and Lee, {Jung Seok} and Choi, {Seong Ho} and Jung, {Ui Won}",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s00784-017-2158-3",
language = "English",
volume = "22",
pages = "829--837",
journal = "Clinical Oral Investigations",
issn = "1432-6981",
publisher = "Springer Verlag",
number = "2",

}

Sinus floor elevation using implants coated with recombinant human bone morphogenetic protein-2 : micro-computed tomographic and histomorphometric analyses. / Thoma, Daniel S.; Yoon, So Ra; Cha, Jae Kook; Lim, Hyun Chang; Lee, Jung Seok; Choi, Seong Ho; Jung, Ui Won.

In: Clinical Oral Investigations, Vol. 22, No. 2, 01.03.2018, p. 829-837.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sinus floor elevation using implants coated with recombinant human bone morphogenetic protein-2

T2 - micro-computed tomographic and histomorphometric analyses

AU - Thoma, Daniel S.

AU - Yoon, So Ra

AU - Cha, Jae Kook

AU - Lim, Hyun Chang

AU - Lee, Jung Seok

AU - Choi, Seong Ho

AU - Jung, Ui Won

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objectives: The objective of this study was to determine the validity of a graft-free sinus floor elevation (SFE) procedure with simultaneous placement of recombinant morphogenetic protein-2 (rhBMP-2)-coated implants compared to uncoated control implants. Methods: In 10 rabbits, SFE was performed on both sides. Dental implants were randomly placed in the sinus filled with a blood clot. Test implants were coated with rhBMP-2, whereas in the control group, implants were uncoated. Micro-computed tomographic and histomophometric analyses were performed at 4 and 8 weeks, including measurement for newly formed bone height (NBHm). Results: Bone formation was evident along the implant surfaces up to the apex in test, but limited in control implants at 4 weeks. NBHm amounted to 5.1 mm (Q1 = 4.1; Q3 = 5.3) for test implants and to 3.4 mm (2.6; 3.7) for control implants at 4 weeks. NBHm then decreased to 8 weeks (3.4 mm (3.3; 3.7)) for test implants, whereas in control sites, NBHm increased slightly to 4.4 mm (4.1; 4.5) (p = 0.1250; p = 0.6250). Conclusions: Implants coated with rhBMP-2 presented a strong osteogenic reaction at 4 weeks with more favorable outcomes in terms of bone formation along the implant surface up to the apex compared to uncoated control implants. Remodeling and resorption process between 4 and 8 weeks did not further improve the outcomes in the test, but in the control group. Clinical relevance: The use of rhBMP-2-coated implants in a graft-free SFE might show an advantage in early implant stability to prevent collapse of membrane. However, a potential clinical benefit still needs to be proven.

AB - Objectives: The objective of this study was to determine the validity of a graft-free sinus floor elevation (SFE) procedure with simultaneous placement of recombinant morphogenetic protein-2 (rhBMP-2)-coated implants compared to uncoated control implants. Methods: In 10 rabbits, SFE was performed on both sides. Dental implants were randomly placed in the sinus filled with a blood clot. Test implants were coated with rhBMP-2, whereas in the control group, implants were uncoated. Micro-computed tomographic and histomophometric analyses were performed at 4 and 8 weeks, including measurement for newly formed bone height (NBHm). Results: Bone formation was evident along the implant surfaces up to the apex in test, but limited in control implants at 4 weeks. NBHm amounted to 5.1 mm (Q1 = 4.1; Q3 = 5.3) for test implants and to 3.4 mm (2.6; 3.7) for control implants at 4 weeks. NBHm then decreased to 8 weeks (3.4 mm (3.3; 3.7)) for test implants, whereas in control sites, NBHm increased slightly to 4.4 mm (4.1; 4.5) (p = 0.1250; p = 0.6250). Conclusions: Implants coated with rhBMP-2 presented a strong osteogenic reaction at 4 weeks with more favorable outcomes in terms of bone formation along the implant surface up to the apex compared to uncoated control implants. Remodeling and resorption process between 4 and 8 weeks did not further improve the outcomes in the test, but in the control group. Clinical relevance: The use of rhBMP-2-coated implants in a graft-free SFE might show an advantage in early implant stability to prevent collapse of membrane. However, a potential clinical benefit still needs to be proven.

UR - http://www.scopus.com/inward/record.url?scp=85021843957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021843957&partnerID=8YFLogxK

U2 - 10.1007/s00784-017-2158-3

DO - 10.1007/s00784-017-2158-3

M3 - Article

C2 - 28681248

AN - SCOPUS:85021843957

VL - 22

SP - 829

EP - 837

JO - Clinical Oral Investigations

JF - Clinical Oral Investigations

SN - 1432-6981

IS - 2

ER -